Licensing status

Publication and contact information


Acute myelogenous leukemia (AML)

Signal regulatory protein-a (SIRPA)

Patient sample and mouse studies suggest disrupting the interaction between SIRPA and CD47 could help treat AML. In a mouse model of human AML, blocking the SIRPA-CD47 interaction with a SIRPA-Fc fusion protein decreased leukemic engraftment compared with using a control IgG4-Fc fusion protein. In samples from patients with AML, the SIRPA-Fc fusion protein increased macrophage-mediated phagocytosis of AML cells compared with the control IgG4-Fc fusion protein. Trillium Therapeutics Inc. and the researchers are running additional in vivo efficacy and pharmacokinetic studies and plan to select a clinical development candidate within 3-4 months.

SciBX 5(37); doi:10.1038/scibx.2012.975
Published online Sept. 20, 2012

Patent application filed; licensed to Trillium Therapeutics

Theocharides, A.P.A. et al. J. Exp. Med.; published online Sept. 3, 2012;
Contact: Jean C.Y. Wang,
University Health Network, Toronto, Ontario, Canada